Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L5 pseudogene 4 (RPL5P4) is a processed pseudogene derived from the parent gene ribosomal protein L5 (RPL5). While the functional RPL5 protein is an essential component of the 60S ribosomal subunit involved in ribosome biogenesis, cell cycle regulation, and tumor suppression[1][2][3], the RPL5P4 pseudogene itself does not code for any protein or functional RNA. Pseudogenes like RPL5P4 are genomic DNA sequences that resemble known genes but lack the ability to produce functional products due to mutations, insertions, or deletions that disrupt normal transcription and translation[3][1]. The clinical and biological importance is specific to the functional RPL5 gene; pseudogenes are generally not considered as therapeutic targets and do not play roles as biomarkers or in disease mechanisms[3][1][2]. If you meant the parent gene/protein RPL5, consult ribosomal protein L5 information instead—it is a validated therapeutic, biomarker, and disease-associated target[1][2][3]. The naming conventions, aliases, and disease relevance (Diamond-Blackfan anemia, cancer, etc.) apply to RPL5, not RPL5P4.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L5 pseudogene 4 (RPL5P4).